In contrast, a recent large registry cohort study by Ueda et al., which utilized data from nationwide registers in Sweden, Denmark, and Norway, found no difference in the risk of intestinal obstruction when comparing GLP-1RAs to SGLT2 inhibitors among over 300,000 patients [16]. Here, SLC5A2 is linked to intestinal obstruction.